Table 5.
Adverse Events During 44 Weeks Maintenance Treatment
| Molindone N=20 |
Olanzapine N=13 |
Risperidone N=21 |
||||
|---|---|---|---|---|---|---|
| Adverse Eventa | N | % | N | % | N | % |
| Any adverse event | 17 | (85) | 13 | (100) | 15 | (71) |
| Weight gain | 7 | (35) | 5 | (38) | 9 | (43) |
| Anxiety | 6 | (30) | 3 | (23) | 5 | (24) |
| Agitation or jitters | 5 | (25) | 3 | (23) | 2 | (10) |
| Drowsiness or sedation | 5 | (25) | 3 | (23) | 2 | (10) |
| Headache | 3 | (15) | 2 | (15) | 5 | (24) |
| Increased appetite | 3 | (15) | 4 | (31) | 3 | (14) |
| Irritability | 6 | (30) | 3 | (23) | 1 | (5) |
| Pacing or restlessness * | 7 | (35) | 1 | (8) | 1 | (5) |
| Depression | 2 | (10) | 3 | (23) | 3 | (14) |
| Sore throat | 4 | (20) | 1 | (8) | 3 | (14) |
| Decreased attention or concentration | 3 | (15) | 3 | (23) | 1 | (5) |
| Nasal congestion | 0 | (0) | 3 | (23) | 4 | (19) |
| Acne | 2 | (10) | 3 | (23) | 1 | (5) |
| Allergies | 0 | (0) | 3 | (23) | 3 | (14) |
Note: Adverse event categories are sorted by decreasing total number of patients with that event.
a
Only those adverse events occurring in >10% of all patients are shown.
*
p<.05 for test of difference across treatment groups